Q1 results: Sun Pharma posts profit, shares surge
Net profit came in at Rs 983 crore for the three months ended June 30, compared with a loss of Rs 425 crore a year earlier
MUMBAI: India’s largest drugmaker Sun Pharmaceutical Industries Ltd posted a first-quarter profit on Tuesday, beating Street estimates. Net profit came in at Rs 983 crore for the three months ended June 30, compared with a loss of Rs 425 crore a year earlier, the company said.
In the year-ago quarter, Sun Pharma incurred costs of Rs 951 crore related to settlements in a US antitrust case over sleep disorder drug Modafinil.
Analysts on average expected a net profit of Rs 897 crore.
Total revenue from operations rose about 16% to Rs 7,224 crore.
Shares of the company ended up 6% on the BSE on Tuesday.
The US arm of Sun Pharmaceutical Industries Ltd recently recalled more than 5,200 units of testosterone cypionate injections from the American market, according to the latest enforcement report of the United States Food and Drug Administration (US FDA). The injections were manufactured by Sun Pharma at its Halol plant.
Editor's Picks »
- Pay scales of 5,254 executives of hydro power PSUs regularised by govt
- Insurance startup Turtlemint raises $25 million from Sequoia, Nexus, Blume Ventures
- Cabinet nods integrated ITR filing system, Infosys to implement ₹4,242 crore project
- Moody’s cautions investors on financials of PSU lender IREDA
- Govt eases procedure for startups to seek tax exemption on investments from angel funds
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms
- Roads sector: Toll collections set to surge, but risks loom for developers